

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office,
Fax No. 1-571-273-0025 on 12-01-04

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT
Docket No.: 019934-000711US

FAX RECEIVED

DEC 1 2004

OFFICE OF PETITIONS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GOSLING et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE BINDING OF
CCX CKR POLYPEPTIDE TO A
CHEMOKINE (AMENDED)

Examiner: Bunner, Bridget E.

Art Unit: 1647

PETITION FOR WAIVER OF 37 C.F.R.
1.67 UNDER 37 C.F.R. 1.183

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants petition to have 37 C.F.R. 1.67 waived in this application
because of the refusal of inventor Michael Hanley to sign a supplemental declaration to
correct the inventive entity.

In support of this petition and to expedite its consideration, Applicants
have attached copies of the following documents that were previously submitted to the
Patent Office by Express Mail on November 30, 2004:

1. Communication Regarding Change in Inventorship;
2. Request to Correct Inventorship under 37 C.F.R. 1.48(a);
3. Declaration under 37 C.F.R. 1.48(a) from Dale Talbot;
4. Declaration signed by all the correct inventors, except Michael

Hanley;

GOSLING et al.
Application No.: 09/721,341
Page 2

PATENT

5: Consent of Assignee for Correction of Inventorship under 37

C.F.R. 1.48(a);

6. Statement under 37 C.F.R. 3.73(b) from assignee

ChemoCentryx;

7. Petition under 37 C.F.R. 1.47(a) and accompanying

Attachments A-D.

Applicants authorize the Patent Office to charge the petition fee of \$130 for this petition under 37 C.F.R. 1.183 to Deposit Account 20-1430. If this authorization is duplicative of the prior authorization to charge the petition fee under 37 C.F.R. 1.47(a) (see Applicants' November 30, 2004 filing), then Applicants request that the prior authorization of payment for the petition under 37 C.F.R. 1.47(a) be applied to the current petition under 37 C.F.R. 1.183. If any additional amount or other fee is due for consideration of this petition, the Office is further authorized to charge such fee to Deposit Account No. 20-1430.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (303) 571-4000.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (303) 571-4000
Fax: (415) 576-0300
SLA:sla

"Express Mail" Label No. EV 291376412 US

Date of Deposit November 29, 2004

PATENT
Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE BINDING
OF CCX CKR POLYPEPTIDE TO
A CHEMOKINE (AMENDED)

Customer No: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

COMMUNICATION REGARDING
CHANGE IN INVENTORSHIP

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This paper and accompanying documents are filed to correct inventorship in this application, specifically to delete Dale Talbot as a named inventor, who was named as an inventor in error without deceptive intent.

In accordance with the requirements of 37 C.F.R. 1.48(a), the following documents are attached:

- (1) Request to Correct Inventorship under 37 C.F.R. 1.48(a);

Jennifa Gosling et al.
Application No.: 09/721,341
Page 2

PATENT

(2) Statement from Dale Talbot stating that it was through error without deceptive intent that he was named as an inventor in the above-identified patent application;

(3) Executed declarations by joint inventors Jennifa Gosling, Daniel J. Dairaghi, Zhenhua Miao and Thomas J. Schall in accordance with 37 C.F.R. §1.63;

(4) Statement Under 37 C.F.R. 3.73(b) signed by Thomas J. Schall on behalf of ChemoCentryx, Inc.;

(5) Written consent from the assignee, ChemoCentryx, Inc., to the change in inventorship; and

(6) Authorization to deduct the request fee of \$130.00, pursuant to 37 C.F.R. §1.17(i), from Deposit Account No. 20-1430 of the undersigned.

Inventor Michael Hanley did not provide an executed declaration listing the correct inventors despite being provided with the documents necessary to effectuate the change in inventorship (i.e., copy of application, currently pending claims and new declaration listing the correct inventors) and being contacted multiple times regarding this matter, thus evidencing a refusal to sign the necessary new declaration. Accordingly, a petition under 37 C.F.R. 1.47(a) is also enclosed to change the inventorship when a joint inventor refuses to join in executing a declaration.


The Patent Office is authorized to charge all fees associated with the request for correction of inventorship and the petition under 37 C.F.R. 1.47(a) to Deposit Account No. 20-1430. Any other fees can also be charged to this Deposit Account.

Jennifa Gosling et al.
Application No.: 09/721,341
Page 3

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (303) 571-4000.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (303) 571-4000
Fax: (415) 576-0300
SLA:sla
60365459 v1